抗生素治疗对嗜麦芽窄食单胞菌所致呼吸机相关性肺炎预后的影响
该回顾性研究纳入2010至2018年法国留尼汪岛大学医院ICU连续130例嗜麦芽窄食单胞菌所致VAP患者,中位SOFA评分58[43-73],中位机械通气12[5-18]天后发生VAP,44.6%为混合感染,ICU死亡率50.0%。多因素Cox回归显示,恰当抗生素治疗(尤其甲氧苄啶-磺胺甲噁唑)与ICU死亡率降低相关(HR 0.42;95%CI 0.24-0.74,p=0.003),与住院死亡率降低相关(HR 0.47;95%CI 0.28-0.79,p=0.04);而抗生素启动时间、联合治疗及疗程对ICU死亡率无影响(p>0.5)。作者认为恰当抗生素治疗可改善此类患者预后。
要点
- 130例嗜麦芽窄食单胞菌VAP患者中,ICU死亡率为50.0%,恰当抗生素治疗与ICU死亡率降低相关(HR 0.42;95%CI 0.24-0.74,p=0.003)。
- 恰当抗生素治疗(尤其甲氧苄啶-磺胺甲噁唑)与住院死亡率降低相关(HR 0.47;95%CI 0.28-0.79,p=0.04)。
- 多因素分析中,年龄较大(HR 1.03;95%CI 1.01-1.04,p=0.001)和VAP发病当日SOFA评分较高(HR 1.08;95%CI 1.03-1.14,p=0.002)与ICU死亡率升高相关。
- 抗生素启动时间、联合治疗及恰当抗生素疗程对ICU死亡率无影响(p>0.5)。
- VAP中44.6%为混合感染,中位机械通气12[5-18]天后发生VAP,中位SAPS II为58[43-73]。
适用人群与场景
- 2010至2018年在法国留尼汪岛(印度洋地区)某大学医院ICU住院、连续发生嗜麦芽窄食单胞菌所致VAP的成人患者,共130例。
- 中位简化急性生理评分II为58[43-73],中位机械通气12[5-18]天后发生VAP;44.6%为混合感染。
研究设计与关键结果
- 研究类型:回顾性研究;样本量130例;单中心(法国留尼汪岛某大学医院ICU);人群为嗜麦芽窄食单胞菌所致VAP患者。
- ICU死亡率为50.0%;VAP为混合感染的比例为44.6%。
- 多因素Cox回归:年龄较大与ICU死亡率升高相关(HR 1.03;95%CI 1.01-1.04,p=0.001);VAP发病当日SOFA评分较高与ICU死亡率升高相关(HR 1.08;95%CI 1.03-1.14,p=0.002)。
- 恰当抗生素治疗(尤其甲氧苄啶-磺胺甲噁唑)与ICU死亡率降低相关(HR 0.42;95%CI 0.24-0.74,p=0.003),与住院死亡率降低相关(HR 0.47;95%CI 0.28-0.79,p=0.04)。
- 抗生素启动时间、联合治疗及恰当抗生素疗程对ICU死亡率无影响(p>0.5)。
证据类型、等级与局限
- 证据类型:回顾性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在嗜麦芽窄食单胞菌所致VAP患者中,恰当抗生素治疗(尤其甲氧苄啶-磺胺甲噁唑)与ICU及住院死亡率降低相关;抗生素启动时间、联合治疗及疗程对ICU死亡率无影响(p>0.5)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Ventilator-associated pneumonia (VAP) caused by Stenotrophomonas maltophilia is poorly described in the literature. However, it has been shown to be associated with increased morbidity and mortality. Probabilistic antibiotic therapy against S. maltophilia is often ineffective as this pathogen is resistant to many antibiotics. There is no consensus at present on the best therapeutic strategy to adopt (class of antibiotics, antibiotic combination, dosage, treatment duration). The aim of this study was to evaluate the effect of antibiotic therapy strategy on the prognosis of patients with VAP caused by S. maltophilia.
RESULTS: This retrospective study evaluated all consecutive patients who developed VAP caused by S. maltophilia between 2010 and 2018 while hospitalized in the intensive care unit (ICU) of a French university hospital in Reunion Island, in the Indian Ocean region. A total of 130 patients with a median Simplified Acute Physiology Score II of 58 [43-73] had VAP caused by S. maltophilia after a median duration of mechanical ventilation of 12 [5-18] days. Ventilator-associated pneumonia was polymicrobial in 44.6% of cases, and ICU mortality was 50.0%. After multivariate Cox regression analysis, the factors associated with increased ICU mortality were older age (hazard ratio (HR): 1.03; 95% CI 1.01-1.04, p = 0.001) and high Sequential Organ Failure Assessment score on the day of VAP onset (HR: 1.08; 95% CI 1.03-1.14, p = 0.002). Appropriate antibiotic therapy, and in particular trimethoprim-sulfamethoxazole, was associated with decreased ICU mortality (HR: 0.42; 95% CI 0.24-0.74, p = 0.003) and decreased hospital mortality (HR: 0.47; 95% CI 0.28-0.79, p = 0.04). Time to start of appropriate antibiotic therapy, combination therapy, and duration of appropriate antibiotic therapy had no effect on ICU mortality (p > 0.5).
CONCLUSION: In our study, appropriate antibiotic therapy, and in particular trimethoprim-sulfamethoxazole, was associated with decreased ICU and hospital mortality in patients with VAP caused by S. maltophilia.
参考来源
- Puech B, Canivet C, Teysseyre L, et al. Effect of antibiotic therapy on the prognosis of ventilator-associated pneumonia caused by Stenotrophomonas maltophilia. Ann Intensive Care. 2021. PMID: 34825962. doi:10.1186/s13613-021-00950-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。